Focus: Illumina is a leading genomic tools and next-generation sequencing (NGS) platform company founded in 1998, headquartered in Hayward, CA. The company specializes in molecular diagnostics and research products spanning oncology, infectious diseases, neurology, and other therapeutic areas.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Hot — 102 jobs added in 30d
Net +42 (102 new, 60 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 16 affected
Source: state DOL filings via Big Local News
Strong technical/engineering opportunity in a genomics leader, but recent layoff activity and organizational restructuring present job security concerns for non-technical roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Illumina
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Illumina's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Sustained layoff activity across 12 months indicates financial/operational stress; job security uncertain even for technical hires.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo